Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

A recently completed study indicates that circulatory protein levels can provide important information for increasingly accurate diagnoses and personalised care in patients with aggressive B-cell ...

Kite, a Gilead Company, has presented new findings demonstrating the safety, efficacy and quality of life benefits offered by ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy PET scans and clinical ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...